RedHill Biopharma Wins $1.8M Legal Costs, Totaling $10.05M

TL;DR

RedHill just got awarded $1.8M in legal costs, on top of their $8.25M win. Big payday!

AI Summary

RedHill Biopharma Ltd. announced on August 20, 2025, that the New York Supreme Court awarded them $1.8 million in legal costs and expenses. This award is in addition to a prior $8.25 million summary judgment win, bringing the total awarded amount to $10.05 million.

Why It Matters

This significant legal victory provides RedHill Biopharma with substantial financial recovery, bolstering its financial position and potentially freeing up resources for its core business operations.

Risk Assessment

Risk Level: medium — While a legal victory is positive, the company's overall financial health and the specifics of the underlying legal dispute could still pose risks.

Key Numbers

• $1.8M — Legal Costs Awarded (Additional amount awarded by the New York Supreme Court.)
• $8.25M — Prior Summary Judgment (Amount won in a previous legal decision.)
• $10.05M — Total Awarded (Combined amount from the summary judgment and legal costs.)

Key Players & Entities

• RedHill Biopharma Ltd. (company) — The company that received the legal award.
• New York Supreme Court (company) — The court that issued the award.
• $1.8 million (dollar_amount) — Legal costs and expenses awarded.
• $8.25 million (dollar_amount) — Prior summary judgment win.
• $10.05 million (dollar_amount) — Total awarded amount.

FAQ

Key Financial Figures

• $1.8 Million — nt entitled: "RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York
• $8.25 Million — Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win". This Form 6-K i
• $1.82 million — Court has awarded RedHill approximately $1.82 million in legal costs and expenses following
• $8.25 million — prior summary judgment of approximately $8.25 million in favor of RedHill in its action again
• $8.25 million — against Kukbo Co. Ltd's ("Kukbo"); the $8.25 million and $1.82 million awards include 9% o

Filing Documents

• zk2533687.htm (6-K) — 27KB
• image00001.jpg (GRAPHIC) — 332KB
• 0001178913-25-002996.txt ( ) — 485KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: August 20, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer 2 Press Release RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win The New York Supreme Court has awarded RedHill approximately $1.82 million in legal costs and expenses following, and in addition to, the Court's prior summary judgment of approximately $8.25 million in favor of RedHill in its action against Kukbo Co. Ltd's ("Kukbo"); the $8.25 million and $1.82 million awards include 9% ongoing statutory interest accrual RALEIGH, N.C., and TEL-AVIV, Israel, August 20, 2025 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court has awarded RedHill approximately $1.82 million in legal costs and expenses (including interest) in its action against Kukbo. The award follows, and is in addition to, the New York Supreme Court's prior summary judgement award of approximately $8.25 million (including interest) in favor of RedHill. 9% ongoing statutory interest accrual is applicable to both the original summary judgment and the award of legal costs and expenses. RedHill also succeeded in its application to Korea's Incheon District Court for an attachment grant against Kukbo. This provides a court-ordered seizure (attachment) of Kukbo's assets, preventing their disposal prior to judgment enforcement. Kukbo appealed the summary judgment decision on December 4, 2024, and the parties have since completed briefing on that appeal with oral argument tentatively scheduled for the September term. Kukbo also has a right to se

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements, including, but not limited to, statements regarding the intended use of net proceeds from the offering, may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding the risk that the Company will not comply with the listing requirements of the Nasdaq Capital Market ("Nasdaq") to remain listed for trading on Nasdaq, the addition of new revenue generating products, out-licensing of the Company's development pipeline assets, timing of opaganib's development for Acute Radiation Syndrome, non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, market and other conditions, the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Kukbo appeal is successful ; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication, the risk that observations from preclinical studies are not indicative or predictive of results in

View Full Filing

View this 6-K filing on SEC EDGAR